ScoreComparison
Why is Kiniksa Pharmaceuticals Ltd. ?
1
With a growth in Net Profit of 108.83%, the company declared Outstanding results in Jun 25
- OPERATING CASH FLOW(Y) Highest at USD 66.94 MM
- DEBT-EQUITY RATIO (HY) Lowest at -60.2 %
- NET SALES(Q) Highest at USD 156.8 MM
2
With ROE of -3.71%, it has a risky valuation with a 2.78 Price to Book Value
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 46.69%, its profits have fallen by -296%
3
High Institutional Holdings at 100%
- These investors have better capability and resources to analyse fundamentals of companies than most retail investors.
4
Consistent Returns over the last 3 years
- Along with generating 46.69% returns in the last 1 year, the stock has outperformed S&P 500 in each of the last 3 annual periods
Real-Time Research ReportHow much should you buy?
- Overall Portfolio exposure to Kiniksa Pharmaceuticals Ltd. should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Kiniksa Pharmaceuticals Ltd. for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Kiniksa Pharmaceuticals Ltd.
109.37%
1.91
47.26%
S&P 500
11.09%
0.96
19.87%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
250.68%
EBIT Growth (5y)
15.28%
EBIT to Interest (avg)
-66.48
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
-0.58
Sales to Capital Employed (avg)
0.79
Tax Ratio
100.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
100.00%
ROCE (avg)
2.12%
ROE (avg)
10.46%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
NA (Loss Making)
Industry P/E
Price to Book Value
2.78
EV to EBIT
-63.53
EV to EBITDA
-70.56
EV to Capital Employed
5.24
EV to Sales
2.09
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
-8.25%
ROE (Latest)
-3.71%
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Bullish (Daily)
KST
Bullish
Bullish
Dow Theory
No Trend
No Trend
OBV
No Trend
No Trend
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend38What is working for the Company
OPERATING CASH FLOW(Y)
Highest at USD 66.94 MM
DEBT-EQUITY RATIO
(HY)
Lowest at -60.2 %
NET SALES(Q)
Highest at USD 156.8 MM
CASH AND EQV(HY)
Highest at USD 576.12 MM
DEBTORS TURNOVER RATIO(HY)
Highest at 20.22%
OPERATING PROFIT(Q)
Highest at USD 20.52 MM
OPERATING PROFIT MARGIN(Q)
Highest at 13.09 %
PRE-TAX PROFIT(Q)
Highest at USD 22.88 MM
NET PROFIT(Q)
Highest at USD 17.83 MM
EPS(Q)
Highest at USD 0.23
-1What is not working for the Company
RAW MATERIAL COST(Y)
Grown by 10.38% (YoY
Here's what is working for Kiniksa Pharmaceuticals Ltd.
Pre-Tax Profit
At USD 22.88 MM has Grown at 1,549.98%
over average net sales of the previous four periods of USD -1.58 MMMOJO Watch
Near term Pre-Tax Profit trend is very positive
Pre-Tax Profit (USD MM)
Net Profit
At USD 17.83 MM has Grown at 520.81%
over average net sales of the previous four periods of USD -4.24 MMMOJO Watch
Near term Net Profit trend is very positive
Net Profit (USD MM)
Net Sales
Highest at USD 156.8 MM and Grown
In each period in the last five periodsMOJO Watch
Near term sales trend is very positive
Net Sales (USD MM)
Debt-Equity Ratio
Lowest at -60.2 % and Grown
In each half year in the last five Semi-Annual periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Operating Cash Flow
Highest at USD 66.94 MM
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (USD MM)
Net Sales
At USD 156.8 MM has Grown at 30.35%
over average net sales of the previous four periods of USD 120.29 MMMOJO Watch
Near term sales trend is positive
Net Sales (USD MM)
Operating Profit
Highest at USD 20.52 MM
in the last five periodsMOJO Watch
Near term Operating Profit trend is positive
Operating Profit (USD MM)
Operating Profit Margin
Highest at 13.09 %
in the last five periodsMOJO Watch
Company's profit margin has improved
Operating Profit to Sales
Pre-Tax Profit
Highest at USD 22.88 MM
in the last five periodsMOJO Watch
Near term Pre-Tax Profit trend is positive
Pre-Tax Profit (USD MM)
Net Profit
Highest at USD 17.83 MM
in the last five periodsMOJO Watch
Near term Net Profit trend is positive
Net Profit (USD MM)
EPS
Highest at USD 0.23
in the last five periodsMOJO Watch
Increasing profitability; company has created higher earnings for shareholders
EPS (USD)
Cash and Eqv
Highest at USD 576.12 MM
in the last six Semi-Annual periodsMOJO Watch
Short Term liquidity is improving
Cash and Cash Equivalents
Debtors Turnover Ratio
Highest at 20.22%
in the last five Semi-Annual periodsMOJO Watch
Company has been able to sell its Debtors faster
Debtors Turnover Ratio
Here's what is not working for Kiniksa Pharmaceuticals Ltd.
Raw Material Cost
Grown by 10.38% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has deteriorated; this may lead to a fall in profit margin
Raw Material Cost as a percentage of Sales
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
